Listed by the USPTO as LEONARD, ARTHUR S
Tech Center 1700 • Art Units: 1631 1633 1643 1651 1798
This examiner grants 50% of resolved cases
LEONARD, ARTHUR S is associated with Tech Center 1700 and Art Unit 1631. The record includes 523 resolved cases, a 50.5% allowance rate, and a 50.4% interview lift. The median time to allowance is 1260 days. The allowance measure indicates that favorable outcomes are not routine in the reported record, while the interview figure shows a strong association between interviews and allowance outcomes.
The listed companies are University of Massachusetts, Massachusetts Institute of Technology, and BASF SE. The listed firms are ARENTFOX SCHIFF LLP, BIRCH STEWART KOLASCH & BIRCH, LLP, and MARSHALL, GERSTEIN & BORUN LLP. Practitioners may give examiner interviews a central role in prosecution planning, while ensuring that discussions are supported by carefully prepared amendments and technical explanations. The median duration also supports early budgeting and realistic scheduling for applicants pursuing allowance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18448499 | KIT FOR PRODUCING ADENO-ASSOCIATED VIRUS, AND USE THEREOF | Final Rejection | FUJIFILM Corporation |
| 18980456 | Targeted CRISPR Delivery Platforms | Non-Final OA | University of Massachusetts |
| 18612111 | Targeted CRISPR Delivery Platforms | Non-Final OA | University of Massachusetts |
| 18053407 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF | Final Rejection | University of Massachusetts |
| 18049724 | COMPLEXES FOR GENE DELETION AND EDITING | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17865375 | Programmable Modification of DNA | Final Rejection | Massachusetts Institute of Technology |
| 17831745 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR GENOME EDITING | Final Rejection | Massachusetts Institute of Technology |
| 18177455 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | Non-Final OA | ModernaTX, Inc. |
| 18372374 | METHOD OF PRODUCING A CELL POPULATION COMPRISING AN AMNION-DERIVED MESENCHYMAL STEM CELL | Final Rejection | KANEKA CORPORATION |
| 17933023 | METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | Final Rejection | BASF PLANT SCIENCE COMPANY GMBH |
| 17933005 | METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | Final Rejection | BASF Plant Science Company GmbH |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18484667 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Final Rejection | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18554139 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS TO ACCEPTOR CELLS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 18036488 | SALICYLIC ACID-INDUCIBLE GENE EXPRESSION COMPOSITIONS AND SYSTEMS FOR CELLS | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 18123413 | METHOD AND SYSTEM FOR DESIGNING POLYNUCLEOTIDE SEQUENCES AND POLYNUCLEOTIDE SEQUENCES OBTAINED THEREBY | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 16959878 | TRANSGENIC EUKARYOTIC ORGANISMS AND METHODS FOR GENDER SELECTION | Final Rejection | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18004122 | THERAPEUTIC NUCLEIC ACIDS, PEPTIDES AND USES I | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18994948 | RECOMBINANT AAV HAVING AAV CLADE D AND CLADE E CAPSIDS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18670290 | COMPOSITIONS AND METHODS FOR TREATING B-LYMPHOID MALIGNANCIES | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18271715 | METHOD FOR CULTURING HUMAN HEPATIC PARENCHYMAL CELL, CULTURED HUMAN HEPATIC PARENCHYMAL CELL, CULTURE MEDIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CULTURE SUPERNATANT OF HUMAN HEPATIC NONPARENCHYMAL CELL | Final Rejection | JSR CORPORATION |
| 18302962 | SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF | Final Rejection | Salk Institute for Biological Studies |
| 18508435 | LIPID FORMULATIONS WITH RNA ENCODING IMMUNOGENS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.5% of resolved applications examined by Arthur S Leonard were allowed (523 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +50.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Arthur S Leonard took 1,260 days on average from filing to allowance.
Arthur S Leonard examines applications in Art Unit 1631 in Tech Center 1700 (Chemistry & Materials).
